ImmuPharma PLC (GB:IMM)
LSE:IMM
Want to see GB:IMM full AI Analyst Report?
Top Page
ImmuPharma
(LSE:IMM)
Select Model
Select Model
Rating:41Neutral
Price Target:
4.50 p
▼(-27.42% Downside)
Action:Reiterated
Date:05/28/26
The score is primarily constrained by weak financial performance (no revenue, continued losses and cash burn, and a fragile equity position), partially offset by low debt. Technicals add modestly negative pressure due to a weak longer-term trend and bearish MACD, while valuation cannot be meaningfully supported with the provided P/E and missing dividend yield.
Positive Factors
Low Leverage
Minimal reported debt materially reduces near-term leverage risk and interest burden, giving management flexibility to prioritize R&D and negotiate partnerships. Over a multi-month horizon this structural de-risking supports options for non-debt financing and preserves solvency buffer.
Negative Factors
No Revenue
Absence of product or licensing revenue forces reliance on external capital to fund operations and development. Over a 2–6 month horizon this structural lack of internal cash generation heightens dilution and financial vulnerability if fundraising windows tighten or milestones slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal reported debt materially reduces near-term leverage risk and interest burden, giving management flexibility to prioritize R&D and negotiate partnerships. Over a multi-month horizon this structural de-risking supports options for non-debt financing and preserves solvency buffer.
Read all positive factors
ImmuPharma (IMM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£27.48M
Dividend YieldN/A
Average Volume (3M)15.00M
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth36.67%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding623,911,400
10 Day Avg. Volume4,827,745
30 Day Avg. Volume14,996,625
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ImmuPharma Business Overview & Revenue Model
Company Description
ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutic solutions. The firm's innovative treatments address a range of medical fields, including autoimmune and inflammatory disorders, a...
How the Company Makes Money
Revenue model details sufficient to describe how ImmuPharma currently makes money (e.g., recurring product sales, disclosed licensing/royalty income, or specific collaboration payments) are null based on the information available here. As a clinic...
ImmuPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 118.35K |
| Gross Profit | -35.30K | -63.88K | -37.61K | -118.00K | 118.35K |
| EBITDA | -2.51M | -2.61M | -3.02M | -2.91M | -8.70M |
| Net Income | -1.81M | -2.48M | -2.92M | -3.81M | -8.17M |
Balance Sheet | |||||
| Total Assets | 1.88M | 977.01K | 2.72M | 3.97M | 6.00M |
| Cash, Cash Equivalents and Short-Term Investments | 1.35M | 236.90K | 208.48K | 667.81K | 1.65M |
| Total Debt | 0.00 | 0.00 | 0.00 | 111.00 | 700.00 |
| Total Liabilities | 1.19M | 1.52M | 1.67M | 1.45M | 1.58M |
| Stockholders Equity | 686.86K | -542.86K | 1.06M | 2.52M | 4.41M |
Cash Flow | |||||
| Free Cash Flow | -2.37M | -1.77M | -1.36M | -2.45M | -4.88M |
| Operating Cash Flow | -2.37M | -1.77M | -1.36M | -2.35M | -4.83M |
| Investing Cash Flow | 6.91K | 1.29M | 188.76K | -77.42K | -50.28K |
| Financing Cash Flow | 3.43M | 500.02K | 722.10K | 1.55M | 702.05K |
ImmuPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | £53.59M | -9.39 | -55.47% | ― | ― | 19.83% | |
53 Neutral | £215.34M | -39.06 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £29.79M | -6.01 | -284.01% | ― | ― | -105.65% | |
47 Neutral | £28.51M | -62.37 | -10.01% | ― | 95.16% | 85.60% | |
42 Neutral | £54.20M | -4.93 | -2807.75% | ― | ― | -28.29% | |
41 Neutral | £27.48M | -7.57 | -1397.43% | ― | ― | 36.67% |
* Healthcare Sector Average
GB:IMM
ImmuPharma
4.41
2.13
93.20%
GB:SAR
Sareum Holdings
21.50
6.75
45.76%
GB:SCLP
Scancell Holdings
20.75
10.97
112.17%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
797.00
622.00
355.43%
GB:SBTX
SkinBioTherapeutics
11.00
-5.63
-33.83%
GB:POLB
Poolbeg Pharma Ltd.
7.60
4.30
130.30%
ImmuPharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
ImmuPharma flags Incanthera board shake-up as chairman steps down
Neutral
Jun 4, 2026
ImmuPharma PLC has highlighted a corporate update from partner company Incanthera plc, noting that Tim McCarthy has stepped down as Executive Chairman of Incanthera as part of wider board changes. The announcement, issued via a non-regulatory comm...
Financial DisclosuresShareholder Meetings
ImmuPharma Sets June AGM as 2025 Annual Report Reaches Shareholders
Neutral
Jun 2, 2026
ImmuPharma PLC has dispatched its Notice of Annual General Meeting and the Annual Report and Accounts for the year ended 31 December 2025 to shareholders, with electronic versions to be made available on the company’s website. The AGM is sch...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
ImmuPharma Narrows Loss, Raises Funds as P140 Autoimmune Platform Advances
Positive
May 27, 2026
ImmuPharma reported a narrowed loss of £1.8m for 2025, stable operating costs and a year-end cash balance of £1.4m, subsequently bolstered by a £6.47m equity raise in April 2026 to support its pipeline. The company advanced its P140...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ImmuPharma Advances Kapiglucagon Diabetes Program With IND-Enabling Plan
Positive
May 5, 2026
ImmuPharma has initiated IND-enabling activities for its Kapiglucagon program, a proprietary glucagon prodrug for Type 1 diabetes, after signing a work order with specialist consultancy tranScrip. The partner will help shape regulatory strategy an...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
ImmuPharma Secures Shareholder Backing and Funding to Drive P140 and Kapiglucagon Programs
Positive
Apr 9, 2026
ImmuPharma has secured strong shareholder backing for its latest fundraising, with more than 88% support for resolutions enabling a £6 million Lanstead subscription and a £468,000 WRAP retail offering. The company says the new capital si...
Private Placements and FinancingShareholder Meetings
ImmuPharma Wins Shareholder Backing for Major Share Allotment
Neutral
Apr 7, 2026
ImmuPharma shareholders have approved two resolutions at a general meeting, authorising directors to allot new equity securities in support of a previously announced fundraising and retail offer. Following the vote, the board allotted a total of 1...
Business Operations and Strategy
ImmuPharma Advances P140 Patent and Data as It Targets 2026 Licensing Deal
Positive
Mar 27, 2026
ImmuPharma has reported progress on its P140 autoimmune technology platform, receiving a supportive first Combined Search and Examination Report for its UK patent application filed in September 2025. The company plans to follow this with a Patent ...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
ImmuPharma Raises £6.47m as Retail Offer Completes Ahead of AIM Share Admission
Positive
Mar 23, 2026
ImmuPharma has completed a WRAP Retail Offer, raising £468,746.82 through the issue of 7,812,447 new shares at the previously announced issue price. Combined with a prior subscription, the company has now secured approximately £6.47m in ...
Private Placements and FinancingShareholder Meetings
ImmuPharma Calls General Meeting to Approve Fundraising Plans
Neutral
Mar 19, 2026
ImmuPharma has published a shareholder circular and formally convened a General Meeting for 7 April 2026 in London, following its recent fundraising announcement. The circular, to be made available on the company’s website, sets out details ...
Business Operations and StrategyPrivate Placements and Financing
ImmuPharma Sets Investor Presentation on Pipeline and £7.5m Fundraise
Positive
Mar 18, 2026
ImmuPharma will host a live investor presentation on the Investor Meet Company platform on 20 March 2026, led by CEO Tim McCarthy, CSO Dr Sébastien Goudreau and COO Dr Tim Franklin. The session will discuss its recent update on the P140 progr...
Private Placements and Financing
ImmuPharma Launches £1.5m WRAP Retail Share Offer Alongside £7.5m Subscription
Neutral
Mar 17, 2026
ImmuPharma has launched a retail equity offer via the Winterflood Retail Access Platform to raise up to £1.5 million by issuing 25 million new ordinary shares at 6 pence each, matching the price of a separate £7.5 million institutional s...
Business Operations and StrategyPrivate Placements and Financing
ImmuPharma raises up to £7.5m to fast‑track Kapiglucagon as P140 licensing talks advance
Positive
Mar 17, 2026
ImmuPharma has secured a £6 million equity subscription from long‑term investor Lanstead Capital at 6 pence per share, with a further £1.5 million to be offered via a UK retail WRAP offer, to accelerate development of Kapiglucagon ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.